Protein Kinase Inhibitors (Variants), Use Thereof in Treating Oncological Diseases and a Pharmaceutical Composition Based Thereon
申请人:Obshchestvo s ogranichennoy otvetstvennostyou "Fusion Pharma"
公开号:US20140213592A1
公开(公告)日:2014-07-31
The present invention relates to the treatment of oncological, chronic inflammatory and similar diseases with the aid of new families of chemical compounds having improved efficiency with regard to the inhibition of Abl kinase and mutant forms thereof, as well as other therapeutically significant kinases. It describes protein kinase inhibitors in the form of compounds of general formula (I) and compounds of general formula (II), or a tautomer, an individual isomer, a mixture of isomers, a pharmaceutically acceptable salt, a solvate or a hydrate thereof.
本发明涉及使用新的化学化合物家族辅助治疗肿瘤、慢性炎症和类似疾病,这些化合物家族在抑制Abl激酶及其突变形式以及其他具有治疗意义的激酶方面具有提高的效率。本发明描述了蛋白激酶抑制剂,其形式为通式(I)和通式(II)的化合物,或其互变异构体、单个异构体、异构体混合物、药学上可接受的盐、溶剂或其水合物。